The PMWC 2021 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
Confirmed Presenting Companies:
The major focus of Dr. Alizadeh’s research group is to attain a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to existing and novel therapies toward improving current treatment strategies. In this effort, they employ tools from functional genomics, computational biology, molecular genetics, and mouse models. They hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.
Dr Volpe graduated from Duke University in 2008 with PhD in computational biology and bioinformatics, with a concentration in immunology. His research involved developing a software algorithm to decipher the germline origins of human immunoglobulin and T-cell receptors and then using that software to analyze large data sets of human antibodies to understand their diversity. He received the American Association of Immunologists-Huang Foundation Young Investigator Award in 2007 for his work in anti-HIV antibody composition. Upon graduating, Dr Volpe worked as a Medical Science Liaison at Monogram Biosciences where he covered the Southeast and Midwest territories. In early 2016 he became the Director of Scientific Outreach, helping to build the Medical Science Liaison team for Labcorp. In early 2018, Dr Volpe began putting together the pieces of what would become Labcorp’s Neurology initiative and he is now the National Segment Director for that program, which covers all of neurology with a focus on neurodegenerative diseases.
Clinical Dx Showcase:
We work day and night, around the world, to deliver answers for all your health questions—whether you’re a provider, drug developer, hospital, medical researcher or patient. That means everything from advancing diagnostic testing, to helping launch new drugs, to offering new perspectives through data, all drawing from a deep well of scientific expertise.
Rule-out Relief: Novel Personalized Alzheimer’s Testing
Biomarkers have long held the promise of deciphering Alzheimer’s disease (AD). Labcorp, in partnership with Cx Precision Medicine, is beginning to fulfill that promise. The test evaluates blood-based biomarkers using a proprietary algorithm to rule patients out of having AD.
Clifford Reid is the founding CEO of Travera. Previously, Dr. Reid was the founding Chairman, President and Chief Executive Officer of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. Prior to Complete Genomics he founded two enterprise software companies: Eloquent (NASDAQ:ELOQ), an internet video company, and Verity (NASDAQ:VRTY), an enterprise search engine company. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University.
Clinical Dx Showcase:
Travera has developed a new biomarker for identifying effective cancer drugs and drug combinations for cancer patients.
A Universal Biomarker For Cancer
Travera has developed a new biomarker for identifying effective cancer drugs and drug combinations for cancer patients. Our novel biomarker matches patients with a wide variety of cancers to a wide variety of cancer drugs.
Dr. MacDonald currently leads ChromaCode’s Data Science and Operations efforts. He is an experienced engineer and manager in the life sciences industry focused on data science, product engineering and process development. He is interested in using modern data science and machine learning approaches to complement tried-and-true industry standard methods for robust design like Design for Six Sigma. His PhD training was in Bioengineering, where he did computational neuroscience work modeling inter-cellular signaling mechanisms in neuro-glial networks at UC San Diego. At Illumina, he was an engineering manager responsible for product engineering and process development for consumables across several major platforms including HiSeqX, helping enable the $1000 genome. He developed numerous tools to monitor and understand the real time performance of worldwide sequencing runs in the cloud and drive continuous product improvement.
Clinical DX Showcase:
ChromaCode is redefining molecular testing through data science by increasing the information content of existing PCR and dPCR tests by 10x, enabling complex precision medicine tests on existing simple, robust technology.
As an accomplished business executive and 25-year veteran of the biotech sector, Dr. Alan Hauser is leveraging his cross-functional leadership experience to create shareholder value for a UC Irvine spatialomics spinout, Arvetas Biosciences. To cross the chasm from multi-omics innovation to profitability in the marketplace, Alan applies his past success encompassing the technical, intellectual property, marketing, corporate development, and operational aspects of commercializing emerging drug-discovery and diagnostics platforms. With a goal of improving people’s lives, his work directed toward planning, promoting, prospecting, appraising plus ROI-led partnering have contributed to launching 9 genomic products, completing > 65 strategic or revenue-generating alliances, and building 9 biotool businesses, including a Silicon Valley startup’s $189 million IPO. Since obtaining his doctorate in chemical and biomolecular engineering at UC Berkeley, Alan completed the executive program at Northwestern’s Kellogg Management Institute as well as additional finance courses at the University of Chicago and Harvard.
Clinical Dx Showcase:
The Arvetas BioSciences single-scan imaging platform, unlike other spatialomic technologies, interrogates the tumor microenvironment of tissue biopsies via RNA/protein detection, so our solution cost-effectively scales as a translational-research and diagnostic tool to enable precision cancer care.
Spatialomics Solution for Disrupting Discovery and Diagnostics
Arvetas BioSciences is addressing significant unmet scientific and medical needs with our multiplexed molecular-marker imaging platform. The single-scan staining solution enables our disparate discovery and diagnostics customers to achieve high-plex spatial transcriptomic and proteomic profiling in an unprecedentedly cost-effective manner.
Dr. Varsha Rao is the Director of Clinical R&D at ClaretBio. She oversees the clinical applications of the novel next-generation sequence assays and analytical pipelines developed at ClaretBio with a main focus on evaluating the utility of cell-free DNA fragmentation patterns in cancer progression and treatment response monitoring. Before joining ClaretBio, she was a Research Scientist at Stanford University School of Medicine in Prof Michael Snyder’s lab. As a part of multiple consortia such as the Integrative Personalized Omics Profiling Project, the Human Microbiome Project and the NASA Twins Study she has worked on longitudinal multiomic analyses, focusing on applying transcriptomics and liquid biopsy approaches to understand nuances of metabolic diseases, cancer, infectious disease and general health. She received her PhD in Molecular and Cellular Biology from University of Maryland Baltimore County in 2012.
Clinical Dx Showcase:
Claret Bioscience’s mission is to improve the quality of NGS data obtained from degraded, highly fragmented, and low yield samples. Our approach aims to provide a complete picture of cfDNA molecules, enhancing the sensitivity of disease screenings, and ultimately improving treatment decisions.
cfDNA Fragmentomic Approach to Precision Oncology
We describe a new approach for cancer disease monitoring that leverages cell-free DNA fragmentation patterns - looking beyond traditional rare somatic mutation detection - with a specific focus on our novel single-stranded library preparation method, SRSLY.
Manu Tamminen is an expert in molecular biology, next- generation DNA sequencing and bioinformatics. He received his PhD from the University of Helsinki and did his post-doctoral research at MIT and ETH Zürich, where he developed methodologies for single cell sequencing and molecular counting. He is currently an Adjunct Professor and Senior Lecturer of Genetics at the University of Turku and has authored several high-impact research publications.
Clinical Dx Showcase:
Genomill Health Inc is a precision diagnostics company with a mission to revolutionize liquid biopsies with their patent-pending Geno1 technology.
Geno1 Permits Highly Scalable Liquid Biopsies
Liquid biopsies are revolutionizing cancer diagnostics but currently suffer from high cost, limited scalability and long turn-around times. Geno1 is a minimalistic, ligation-based workflow which harnessed next-generation DNA sequencing to provide infinitely scalable molecular quantification for liquid biopsies and beyond.
Dr. O’Bryant is the Executive Director of the UNTHSC Institute for Translational Research and Endowed Chair in Pharmacology and Neuroscience. He has spent his entire career working towards the development and implementation of a precision medicine model for advanced diagnostics and therapeutics to better the lives of those suffering from Alzheimer’s disease and other neurodegenerative diseases. He created the AD Blood Test for primary care doctors, which has been validated across multiple cohorts, technologies as well as human and animal models. He has also created a Parkinson’s Disease Blood Test for primary care, a Dementia with Lewy Bodies Blood Test for primary care, as well as an AD Blood Test for adults with Down Syndrome for primary care. He has created multiple technologies to identify subsets of patients suffering from Alzheimer’s disease (and other neurodegenerative diseases) that will benefit from targeted interventions. He is the PI of the HABLE study, which is a community-based study of Alzheimer’s Disease pathology among a multi-ethnic cohort with the goal of identifying and eliminating health disparities through a precision medicine approach. He is PI of the Alzheimer’s Disease in Primary Care (ADPC) study, which is the first-ever study of blood-based biomarkers for screening AD in primary care settings. He has published approximately 200 peer-reviewed publications and has been responsible for nearly $100m in funded research and clinical programs.